Abstract

Huperzine A (HupA), a natural Lycopodium alkaloid primarily derived from Huperzia serrata, has gained attention for its potent neuroprotective properties, particularly its ability to inhibit acetylcholinesterase and modulate key neurological pathways. This review highlights HupA's therapeutic potential in managing neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple sclerosis, Epilepsy, and Myasthenia gravis drawing on a comprehensive literature survey of in vitro, in vivo, and clinical investigation data. Given the limited yield from natural sources, this review also focuses on biotechnological strategies to enhance HupA production. These include chemical synthesis, microbial fermentation using endophytic fungi, plant tissue culture, and emerging synthetic biology approaches. Key biosynthetic intermediates and enzymes, such as lysine decarboxylase, copper amine oxidase, and cytochrome P450s, are discussed in the context of metabolic pathway elucidation and engineering. The review emphasizes the need to bridge current knowledge gaps in HupA biosynthesis to develop cost-effective, sustainable production methods. Advances in metabolic pathway elucidation and engineering hold immense potential for scalable biosynthetic production. Ultimately, the integration of HupA into neurotherapeutic regimens, coupled with innovations in its production, could revolutionize the management of neurodegenerative disorders and position it as a cornerstone of future multi-targeted treatment strategies.